Pages that link to "Q47099537"
Jump to navigation
Jump to search
The following pages link to Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. (Q47099537):
Displaying 13 items.
- PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer. (Q54984581) (← links)
- Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting. (Q55474712) (← links)
- Role of mTOR Signaling in Tumor Microenvironment: An Overview (Q58766017) (← links)
- Novel Factors of Viral Origin Inhibit TOR Pathway Gene Expression (Q59808772) (← links)
- Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells (Q60043947) (← links)
- Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview (Q61795908) (← links)
- Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment (Q89587297) (← links)
- Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease (Q91840007) (← links)
- Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer (Q91995955) (← links)
- Review and update on drugs related to the development of osteonecrosis of the jaw (Q92272586) (← links)
- Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma (Q95322793) (← links)
- Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs (Q98291421) (← links)
- <sup>18</sup>F-meta-fluorobenzylguanidine (<sup>18</sup>F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models (Q103826053) (← links)